share_log

Icosavax Analyst Ratings

Icosavaxアナリストの評価

Benzinga ·  2023/10/02 08:29
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/02/2023 222.58% Oppenheimer → $25 Reiterates Outperform → Outperform
04/25/2023 248.39% Oppenheimer → $27 Reiterates → Outperform
01/04/2023 248.39% Oppenheimer → $27 Initiates Coverage On → Outperform
08/23/2021 William Blair Initiates Coverage On → Outperform
08/23/2021 545.16% Evercore ISI Group → $50 Initiates Coverage On → Outperform
08/23/2021 Cowen & Co. Initiates Coverage On → Outperform
08/23/2021 545.16% Jefferies → $50 Initiates Coverage On → Buy

What is the target price for Icosavax (ICVX)?

The latest price target for Icosavax (NASDAQ: ICVX) was reported by Oppenheimer on October 2, 2023. The analyst firm set a price target for $25.00 expecting ICVX to rise to within 12 months (a possible 222.58% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Icosavax (ICVX)?

The latest analyst rating for Icosavax (NASDAQ: ICVX) was provided by Oppenheimer, and Icosavax reiterated their outperform rating.

When is the next analyst rating going to be posted or updated for Icosavax (ICVX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Icosavax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Icosavax was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.

Is the Analyst Rating Icosavax (ICVX) correct?

While ratings are subjective and will change, the latest Icosavax (ICVX) rating was a reiterated with a price target of $0.00 to $25.00. The current price Icosavax (ICVX) is trading at is $7.75, which is within the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする